本文選題：藥品GMP　切入點(diǎn)：有效實(shí)施　出處：《山東中醫(yī)藥大學(xué)》2013年碩士論文

【摘要】：藥品是保證人民生命健康的特殊產(chǎn)品，藥品質(zhì)量管理具有特殊的重要性。藥品GMP通過(guò)對(duì)藥品生產(chǎn)全過(guò)程進(jìn)行規(guī)范管理，確保制藥企業(yè)遵循科學(xué)、系統(tǒng)的行業(yè)準(zhǔn)則和行為規(guī)范，保證藥品質(zhì)量，維護(hù)人民群眾用藥的安全有效。 藥品GMP于上世紀(jì)80年代初引入我國(guó)，與美國(guó)制藥行業(yè)相比晚了二十多年。我國(guó)藥品GMP經(jīng)歷了四個(gè)發(fā)展階段，即準(zhǔn)備階段、萌芽階段、起步階段、發(fā)展完善階段。經(jīng)過(guò)三十年的發(fā)展演變，我國(guó)藥品GMP取得的進(jìn)步是有目共睹的。通過(guò)實(shí)施GMP，藥品質(zhì)量得到了一定程度的保障，制藥企業(yè)的綜合素質(zhì)得到了很大的提升。但是，還應(yīng)當(dāng)看到，我國(guó)GMP的貫徹實(shí)施還存在許多問(wèn)題，這些問(wèn)題不解決，將嚴(yán)重阻礙我國(guó)制藥工業(yè)的發(fā)展。 經(jīng)過(guò)長(zhǎng)期的努力和發(fā)展，我國(guó)藥品GMP在文本上已經(jīng)同發(fā)達(dá)國(guó)家的GMP相差無(wú)幾，但在實(shí)施層面上，我國(guó)GMP同發(fā)達(dá)國(guó)家GMP還存在著較大的差距，特別是中小型制藥企業(yè)的GMP實(shí)施問(wèn)題更為突出。我國(guó)制藥企業(yè)當(dāng)中，中小型制藥企業(yè)占據(jù)很大的比重，中小型制藥企業(yè)GMP的實(shí)施狀況在很大程度上決定著我國(guó)的藥品質(zhì)量，決定著人民群眾用藥的安全程度。中小型制藥企業(yè)GMP實(shí)施中存在的問(wèn)題，成為影響藥品質(zhì)量的關(guān)鍵和監(jiān)督管理的難點(diǎn)。與此同時(shí)，中小制藥企業(yè)GMP實(shí)施問(wèn)題，也關(guān)系到中小型制藥企業(yè)的長(zhǎng)期穩(wěn)定發(fā)展。所以，探索適合我國(guó)國(guó)情的中小型制藥企業(yè)藥品GMP實(shí)施模式，對(duì)于提升中小企業(yè)GMP實(shí)施水平，保證人民群眾用藥的安全有效，，促進(jìn)我國(guó)制藥企業(yè)健康發(fā)展，具有重要的理論意義和現(xiàn)實(shí)意義。 本文從管理的角度，對(duì)藥品GMP管理的4M要素和國(guó)外中小型制藥企業(yè)藥品GMP管理的先進(jìn)經(jīng)驗(yàn)進(jìn)行研究,弄清我國(guó)中小型制藥企業(yè)GMP實(shí)施的現(xiàn)狀，探討我國(guó)中小型制藥企業(yè)GMP實(shí)施中存在的問(wèn)題，并在此基礎(chǔ)上,提出改進(jìn)我國(guó)中小型制藥企業(yè)GMP實(shí)施的政策建議，為提升我國(guó)藥品GMP實(shí)施水平提供參考，為我國(guó)現(xiàn)存中小型制藥企業(yè)克服危機(jī)迎接挑戰(zhàn)提供發(fā)展思路。
[Abstract]:Medicine is a special product to ensure people's life and health, and drug quality management is of special importance.By regulating the whole process of drug production, GMP ensures that pharmaceutical enterprises follow the scientific and systematic industry standards and behavior norms, ensure the quality of drugs, and maintain the safety and effectiveness of drug use by the people.Drug GMP was introduced into China in the early 1980's, which was more than 20 years late compared with American pharmaceutical industry.Drug GMP in China has undergone four stages of development, namely, preparation stage, budding stage, initial stage and development stage.After 30 years of development and evolution, the progress of drug GMP in China is obvious to all.Through the implementation of GMPs, the quality of drugs has been guaranteed to a certain extent, and the comprehensive quality of pharmaceutical enterprises has been greatly improved.However, it should be noted that there are still many problems in the implementation of GMP in China, which will seriously hinder the development of pharmaceutical industry in China.After a long period of effort and development, the text of Chinese drug GMP is no different from that of developed countries' GMP, but on the implementation level, there is still a big gap between our country's GMP and developed country's GMP.In particular, the implementation of GMP in small and medium pharmaceutical enterprises is more prominent.Among the pharmaceutical enterprises in China, the small and medium-sized pharmaceutical enterprises account for a large proportion, the implementation of small and medium-sized pharmaceutical enterprises to a large extent determines the quality of drugs in China, determines the safety of drug use by the people.The problems existing in the implementation of GMP in small and medium-sized pharmaceutical enterprises have become the key to the quality of drugs and the difficulties of supervision and management.At the same time, the implementation of small and medium-sized pharmaceutical enterprises GMP, but also related to the long-term and stable development of small and medium-sized pharmaceutical enterprises.Therefore, to explore the implementation mode of drug GMP for small and medium-sized pharmaceutical enterprises, which is suitable for our country's national conditions, will promote the level of GMP implementation in small and medium-sized enterprises, ensure the safety and effectiveness of drug use by the people, and promote the healthy development of pharmaceutical enterprises in our country.It has important theoretical and practical significance.From the point of view of management, this paper studies the 4M elements of drug GMP management and the advanced experience of drug GMP management in foreign small and medium-sized pharmaceutical enterprises, and makes clear the current situation of GMP implementation in small and medium-sized pharmaceutical enterprises in China.This paper probes into the problems existing in the implementation of GMP in the small and medium-sized pharmaceutical enterprises in China, and on this basis, puts forward some policy suggestions for improving the implementation of GMP in the small and medium-sized pharmaceutical enterprises in China, and provides a reference for improving the implementation level of the drug GMP in our country.To provide development ideas for existing small and medium-sized pharmaceutical enterprises in China to overcome the crisis and meet the challenges.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類(lèi)號(hào)】：F273.2;F426.72

【參考文獻(xiàn)】

中國(guó)期刊全文數(shù)據(jù)庫(kù) 前10條

1 鄒毅;吳生齊;丁德海;;基于EBGMP理念的藥品GMP認(rèn)證現(xiàn)場(chǎng)檢查工作分析[J];廣東藥學(xué)院學(xué)報(bào);2011年04期

2 李素霞;韓月芝;王剛;邊虹錚;;GMP在藥品生產(chǎn)企業(yè)中的實(shí)踐與應(yīng)用[J];華章;2009年21期

3 魏玉德;藥品監(jiān)督管理人員應(yīng)強(qiáng)化五種意識(shí)[J];時(shí)珍國(guó)醫(yī)國(guó)藥;2001年03期

4 段穎 ,焦楠 ,孟淑芬 ,王磊 ,李傳秋;QA在GMP認(rèn)證企業(yè)中的作用[J];山東醫(yī)藥工業(yè);2003年02期

5 楊曉梅;原料藥GMP認(rèn)證[J];世界最新醫(yī)學(xué)信息文摘;2004年06期

6 梁毅;;藥品GMP特征研究[J];現(xiàn)代管理科學(xué);2011年09期

7 陳旭冰;陳光勇;劉光明;;GMP與cGMP的差異[J];中國(guó)科技信息;2008年16期

8 梁毅;;澳大利亞GMP與我國(guó)GMP的比較分析[J];醫(yī)藥工程設(shè)計(jì);2008年02期

9 梁毅;;構(gòu)建符合我國(guó)藥品生產(chǎn)實(shí)際的GMP管理體系[J];醫(yī)藥工程設(shè)計(jì);2011年03期

10 冀紅;;藥品GMP認(rèn)證現(xiàn)場(chǎng)檢查實(shí)施方法和技巧[J];中國(guó)藥事;2006年06期

本文編號(hào)：1700579